ARS Pharmaceuticals Faces Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, announced a class action lawsuit has been filed on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities. The lawsuit covers the period between March 9, 2026, and June 24, 2026, inclusive.

The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements to the market regarding its products and business operations during the class period. Investors who purchased SPRY stock during this time may have acquired it at inflated prices based on these alleged misrepresentations.

Rosen Law Firm is urging investors who suffered losses in ARS Pharmaceuticals securities to contact the firm to learn more about their rights and the litigation. The firm is investigating the claims and seeking to recover damages for affected shareholders.

The legal action is proceeding in the United States, aiming to provide recourse for investors who believe they were harmed by the company's alleged conduct. ARS Pharmaceuticals has not yet issued a formal response to the lawsuit.